CN Patent

CN114599364A — 用于减少特应性皮炎瘙痒的鲁索替尼制剂

Assigned to Incyte Corp · Expires 2022-06-07 · 4y expired

What this patent protects

本公开涉及通过每天两次施用局部0.75％或1.5％鲁索替尼乳膏来减少特应性皮炎患者的瘙痒和治疗特应性皮炎患者的方法。

USPTO Abstract

本公开涉及通过每天两次施用局部0.75％或1.5％鲁索替尼乳膏来减少特应性皮炎患者的瘙痒和治疗特应性皮炎患者的方法。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN114599364A
Jurisdiction: CN
Classification: —
Expires: 2022-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.